Todd Grinnell, PhD

Executive Director, Medical
Axsome Therapeutics, New York, NY, USA

Poster(s):

• (134) Budget impact of Symbravo® (MoSEIC™ meloxicam and rizatriptan) to health plans in the United States for the acute treatment of migraine in adults
  Wednesday, October 29, 2025